Citation Impact
Citing Papers
Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial
2012 Standout
Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases
2007 Standout
Trichuris suis therapy in Crohn’s disease
2004
Utilisation of erythrocyte 6-thioguanine metabolite levels to optimise azathioprine therapy in patients with inflammatory bowel disease
2001
Predicting outcome in severe ulcerative colitis.
1996
Colectomy rate in steroid-refractory colitis initially responsive to cyclosporin: a long-term retrospective cohort study
2007
Anti-TNF strategies in stenosing and fistulizing Crohn?s disease
2004
Maintenance treatment of Crohn's disease
2003
Predictive Factors of Response to Cyclosporine in Steroid-Refractory Ulcerative Colitis
2008
European evidence based consensus on the diagnosis and management of Crohn’s disease: current management
2006
Vagus nerve stimulation attenuates the systemic inflammatory response to endotoxin
2000 StandoutNature
Infliximab for acute, not steroid-refractory ulcerative colitis
2004
Conventional Medical Management of Inflammatory Bowel Disease
2011
Etanercept for active Crohn's disease: A randomized, double-blind, placebo-controlled trial
2001
Review article: monitoring of immunomodulators in inflammatory bowel disease
2005
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
2013 Standout
A new look at toxic megacolon: an update and review of incidence, etiology, pathogenesis, and management
2003
Intravenous CDP870, a PEGylated Fab′ fragment of a humanized antitumour necrosis factor antibody, in patients with moderate‐to‐severe Crohn's disease: an exploratory study
2004
Clinical Outcome Following Treatment of Refractory Inflammatory and Fistulizing Crohn's Disease With Intravenous Cyclosporine
1998
Predicting the outcome of severe ulcerative colitis: development of a novel risk score to aid early selection of patients for second‐line medical therapy or surgery
2004
Adalimumab for maintenance treatment of Crohn’s disease: results of the CLASSIC II trial
2007
Contemporary Morphologic Definition of Backwash Ileitis in Ulcerative Colitis and Features That Distinguish It From Crohn Disease
2006
Infliximab in the Treatment of Severe, Steroid-Refractory Ulcerative Colitis: A Pilot Study
2001
Ulcerative Colitis
2011 Standout
Unravelling the pathogenesis of inflammatory bowel disease
2007 StandoutNature
CDP571, a humanised monoclonal antibody to tumour necrosis factor α, for moderate to severe Crohn’s disease: a randomised, double blind, placebo controlled trial
2004
Long-term Outcome of Treatment with Intravenous Cyclosporin in Patients With Severe Ulcerative Colitis
2004
Unfractionated or low-molecular weight heparin for induction of remission in ulcerative colitis
2010
Evaluation of the clinical course of acute attacks in patients with ulcerative colitis through the use of an activity index
2002
Oral tacrolimus long‐term therapy in patients with Crohn’s disease and steroid resistance
2001
the risks of malignancy from either immuno‐suppression or diagnostic radiation in inflammatory bowel disease
1995
A retrospective analysis of the efficacy and safety of infliximab as rescue therapy in acute severe ulcerative colitis
2007
Guidelines for the management of inflammatory bowel disease in adults
2011
Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis
2005
Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's Disease
2003 Standout
Autoimmunity associated with anti-tumor necrosis factor α treatment in Crohn’s disease: a prospective cohort study
2003
A cytokine-mediated link between innate immunity, inflammation, and cancer
2007 Standout
The current future understanding of inflammatory bowel disease
2002
Inflammatory bowel disease: clinical aspects and established and evolving therapies
2007 Standout
Ulcerative Colitis Practice Guidelines in Adults (Update): American College of Gastroenterology, Practice Parameters Committee
2004 Standout
Crohn's disease
2012 Standout
CDP571, a humanized monoclonal antibody to tumour necrosis factor‐α, for steroid‐dependent Crohn's disease: a randomized, double‐blind, placebo‐controlled trial
2006
Inhibition of α-helix-mediated protein–protein interactions using designed molecules
2013
A randomised dose finding study of oral tacrolimus (FK506) therapy in refractory ulcerative colitis
2006
Infliximab for patients with refractory ulcerative colitis
2001
Ulcerative colitis
2002
A Short-Term Study of Chimeric Monoclonal Antibody cA2 to Tumor Necrosis Factor α for Crohn's Disease
1997 Standout
Regulation of inflammatory responses by gut microbiota and chemoattractant receptor GPR43
2009 StandoutNature
The natural history of corticosteroid therapy for inflammatory bowel disease: A population-based study
2001 Standout
Inflammatory bowel disease: cause and immunobiology
2007 Standout
Factors predictive of response to cyclosporin treatment for severe, steroid-resistant ulcerative colitis
2000
Inflammatory Bowel Disease
2009 Standout
Proximal Crohn's Disease: Review of the Clinicopathologic Features and Therapy
2001
Biologic therapy of inflammatory bowel disease
2002
Early Mucosal Healing With Infliximab Is Associated With Improved Long-term Clinical Outcomes in Ulcerative Colitis
2011
Role of the Microbiota in Immunity and Inflammation
2014 Standout
Metagenomic biomarker discovery and explanation
2011 Standout
Intravenous Cyclosporin in Ulcerative Colitis: A Five-Year Experience
1999
Cyclosporine and Infliximab as Rescue Therapy for Each Other in Patients With Steroid-Refractory Ulcerative Colitis
2008
Ciclosporin use in acute ulcerative colitis
2005
Biological Therapies for Inflammatory Bowel Diseases
2009
Activation-Induced Cytidine Deaminase Links Between Inflammation and the Development of Colitis-Associated Colorectal Cancers
2008 StandoutNobel
Nicotine inhibits the in vitro production of interleukin 2 and tumour necrosis factor-α by human mononuclear cells
1996
A Computationally Designed Inhibitor of an Epstein-Barr Viral Bcl-2 Protein Induces Apoptosis in Infected Cells
2014 StandoutNobel
Intravenous Cyclosporine in Refractory Pyoderma Gangrenosum Complicating Inflammatory Bowel Disease
2001
Ulcerative colitis
2012 Standout
Systematic review: infliximab therapy in ulcerative colitis
2006
Medical management of left-sided ulcerative colitis and ulcerative proctitis: Critical evaluation of therapeutic trials
2006
Infliximab Maintenance Therapy for Fistulizing Crohn's Disease
2004 Standout
Crohn's disease
2016 Standout
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
2016 Standout
Ankylosing spondylitis
2007 Standout
Inflammatory Bowel Disease
2002 Standout
The Impact of the Gut Microbiota on Human Health: An Integrative View
2012 Standout
Colectomy Rate Comparison After Treatment of Ulcerative Colitis With Placebo or Infliximab
2009
Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination
2016
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial
2002 Standout
Optimizing anti-tumor necrosis factor strategies in inflammatory bowel disease
2003
Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: A randomized controlled trial
2003
Urgent Subtotal Colectomy for Severe Inflammatory Bowel Disease
2004
Fulminant Colitis
2008
Randomized, double-blind comparison of 4 mg/kg versus 2 mg/kg intravenous cyclosporine in severe ulcerative colitis1 1Gert Van Assche, Severine Vermeire, Geert D’Haens, and Paul Rutgeerts have been instrumental in the design of the study, trial management, data analysis, and writing the paper. Maja Noman had a major contribution in the clinical ambulatory follow-up of the patients in the trial. Martin Hiele followed cyclosporine levels and adjusted drug doses of patients in the trial and provided statistical advice. Katrien Asnong was the study coordinator and had a major share in data analysis. Joris Arts analyzed safety data and followed patients clinically during the trial. Andre D’Hoore and Freddy Penninckx performed the surgical interventions in patients failing the trial and substantially contributed in evaluating patients for colectomy.
2003
6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease
2002
Medical therapy for ulcerative colitis 2004
2004
Recognition of Commensal Microflora by Toll-Like Receptors Is Required for Intestinal Homeostasis
2004 Standout
Endoscopic tri-modal imaging for surveillance in ulcerative colitis: randomised comparison of high-resolution endoscopy and autofluorescence imaging for neoplasia detection; and evaluation of narrow-band imaging for classification of lesions
2008
Mechanisms of Disease: pathogenesis of Crohn's disease and ulcerative colitis
2006
Ulcerative colitis
2016 Standout
Pharmacokinetic Considerations in the Treatment of Inflammatory Bowel Disease
2001
The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management
2010
Inflammatory Bowel Disease
1996
Ulcerative Colitis Practice Guidelines in Adults: American College of Gastroenterology, Practice Parameters Committee
2010
Azathioprine or 6-Mercaptopurine Before Colectomy for Ulcerative Colitis Is Not Associated With Increased Postoperative Complications
2002
Effect of butyrate enemas on inflammation and antioxidant status in the colonic mucosa of patients with ulcerative colitis in remission
2010
Incidence of Colectomy During Long-term Follow-up After Cyclosporine-Induced Remission of Severe Ulcerative Colitis
2006
MEDICAL THERAPY FOR INFLAMMATORY BOWEL DISEASE
1999
Intravenous cyclosporine versus intravenous corticosteroids as single therapy for severe attacks of ulcerative colitis
2001
Treatment of ulcerative colitis by feeding with germinated barley foodstuff: first report of a multicenter open control trial
2002
Interferon-β-1a for the Treatment of Steroid-Refractory Ulcerative Colitis: A Randomized, Double-Blind, Placebo-Controlled Trial
2005
Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised controlled trial
2003
A microbial symbiosis factor prevents intestinal inflammatory disease
2008 StandoutNature
The Toronto Consensus Statements for the Management of Inflammatory Bowel Disease in Pregnancy
2015
Confocal laser endomicroscopy is a new imaging modality for recognition of intramucosal bacteria in inflammatory bowel disease in vivo
2010
Repertoires of Autophagy in the Pathogenesis of Ocular Diseases
2015 Standout
Ipilimumab-induced acute severe colitis treated by infliximab
2013
Steroid-unresponsive acute attacks of inflammatory bowel disease: immunomodulation by tacrolimus (FK506)
1998
The Origin and Functions of Multiple Human Glucocorticoid Receptor Isoforms
2004
Successive Treatment With Cyclosporine and Infliximab in Steroid-Refractory Ulcerative Colitis
2011
Cyclosporin for severe ulcerative colitis does not increase the rate of perioperative complications
2001
Quantitive Cytokine mRNA Expression Profiles in the Colonic Mucosa of Patients with Steroid Naïve Ulcerative Colitis During Active and Quiescent Disease
2008
Infliximab in severe ulcerative colitis: short‐term results of different infusion regimens and long‐term follow‐up
2007
Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease
2010 Standout
Immunosuppressive drugs in ulcerative colitis: twisting facts to suit theories?
2006
Surgery for Inflammatory Bowel Diseases
2003
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
2013 Standout
Soil-transmitted helminth infections: ascariasis, trichuriasis, and hookworm
2006 Standout
American Gastroenterological Association Institute Technical Review on Corticosteroids, Immunomodulators, and Infliximab in Inflammatory Bowel Disease
2006
Management of Crohn's Disease in Adults
2009 Standout
6‐Tioguanine monitoring in steroid‐dependent patients with inflammatory bowel diseases receiving azathioprine
2005
Colectomy rate in acute severe ulcerative colitis in the infliximab era
2008
Optimizing anti-TNF treatment in inflammatory bowel disease
2004
A global consensus on the classification, diagnosis and multidisciplinary treatment of perianal fistulising Crohn's disease
2014
Therapy of inflammatory bowel disease
2000
Guidelines for the management of inflammatory bowel disease in adults
2004
Subtotal Colectomy for Severe Acute Colitis: A 20-Year Experience of a Tertiary Care Center with an Aggressive and Early Surgical Policy
2003
Binding and Functional Comparisons of Two Types of Tumor Necrosis Factor Antagonists
2002
Sympathetic Neural Mechanisms of Cyclosporine-Induced Hypertension*
1996
Prevalence of cytomegalovirus infection in severe refractory ulcerative and Crohn's colitis
2001
Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
2005 Standout
The gut microbiota shapes intestinal immune responses during health and disease
2009 Standout
An Evidence-Based Systematic Review on Medical Therapies for Inflammatory Bowel Disease
2011
Gut Microbiota in Health and Disease
2010 Standout
Tumour necrosis factor alpha blocking agents for induction of remission in ulcerative colitis
2006
Prevalence of cytomegalovirus infection in severe refractory ulcerative and Crohn's colitis
2001
Clinical Practice Guideline for the Surgical Management of Crohn’s Disease
2015
[American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease].
2007
Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
2018 Standout
Expression and Subcellular Distribution of the β-Isoform of the Human Glucocorticoid Receptor*
1997
European evidence-based Consensus on the diagnosis and management of ulcerative colitis: Definitions and diagnosis
2008
Tumor necrosis factor-alpha antibody for induction of remission in Crohn's disease
2003
Infliximab as Rescue Therapy in Severe to Moderately Severe Ulcerative Colitis: A Randomized, Placebo-Controlled Study
2005
Cyclosporin for severe ulcerative colitis.
2000
How Do Glucocorticoids Influence Stress Responses? Integrating Permissive, Suppressive, Stimulatory, and Preparative Actions*
2000 Standout
The microbial metabolite butyrate regulates intestinal macrophage function via histone deacetylase inhibition
2014 Standout
Antiinflammatory Action of Glucocorticoids — New Mechanisms for Old Drugs
2005 Standout
Cyclosporine A-induced hypertension involves synapsin in renal sensory nerve endings
2000 StandoutNobel
A Review of Activity Indices and Efficacy End Points for Clinical Trials of Medical Therapy in Adults With Ulcerative Colitis
2006 Standout
TNF‐mediated inflammatory disease
2007 Standout
European evidence-based Consensus on the management of ulcerative colitis: Current management
2008
Efficacy and Safety of Tumor Necrosis Factor Antagonists in Crohn's Disease: Meta-Analysis of Placebo-Controlled Trials
2008
MyD88 signaling in nonhematopoietic cells protects mice against induced colitis by regulating specific EGF receptor ligands
2010 StandoutNobel
Daclizumab, a humanised monoclonal antibody to the interleukin 2 receptor (CD25), for the treatment of moderately to severely active ulcerative colitis: a randomised, double blind, placebo controlled, dose ranging trial
2006
Tacrolimus (FK506) for induction of remission in refractory ulcerative colitis
2008
A critical review of cyclosporine therapy in inflammatory bowel disease
1995
Adverse Events Associated With the Use of Cyclosporine in Patients With Inflammatory Bowel Disease
2008
Works of D. H. Present being referenced
Fistula response to methotrexate in Crohn's disease: a case series
2003
The CHOICE trial: adalimumab demonstrates safety, fistula healing, improved quality of life and increased work productivity in patients with Crohn’s disease who failed prior infliximab therapy
2010
Cyclosporine in Severe Ulcerative Colitis Refractory to Steroid Therapy
1994
An engineered human antibody to TNF (CDP571) for active Crohn's disease: A randomized double-blind placebo-controlled trial
2001
Crohn's disease of the duodenum associated with pancreatitis: a case report and review of the literature.
1987
A Randomized Placebo-Controlled Trial of Infliximab Therapy for Active Ulcerative Colitis
2005